• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • Myinsights
  • MYBoard
  • Strategy & Consulting
Select Page

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia

by | Feb 5, 2025 | Publications

Front Oncol. 2025 Jan 21;14:1535869. doi: 10.3389/fonc.2024.1535869. eCollection 2024. ABSTRACT BACKGROUND: Regulatory bodies have recently approved chimeric antigen receptor (CAR)-T cell therapies for patients with multiple myeloma (MM), but the treatment process...

A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy

by | Feb 4, 2025 | Publications

Anticancer Agents Med Chem. 2025 Jan 30. doi: 10.2174/0118715206350342241224073809. Online ahead of print. ABSTRACT BACKGROUND: Despite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common,...

Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis

by | Jan 28, 2025 | Publications

Ther Adv Hematol. 2025 Jan 27;16:20406207251314289. doi: 10.1177/20406207251314289. eCollection 2025. ABSTRACT BACKGROUND: Anti-CD38 monoclonal antibodies (mAbs) have significantly changed the multiple myeloma treatment landscape. This meta-analysis compared the...

Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes

by | Jan 8, 2025 | Publications

Ann Hematol. 2024 Dec;103(12):5849-5859. doi: 10.1007/s00277-024-06129-5. Epub 2024 Dec 7. ABSTRACT Patient-reported outcomes (PROs) are crucial endpoints in multiple myeloma (MM) randomized controlled trials (RCTs), yet there is significant variability in their...

Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials

by | Jan 7, 2025 | Publications

Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):32-44. doi: 10.1016/j.clml.2024.09.008. Epub 2024 Sep 21. ABSTRACT BACKGROUND: The efficacy of elotuzumab, an anti-SLAMF7 monoclonal antibody, in treating relapsed/refractory multiple myeloma (RRMM) and newly-diagnosed...

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma

by | Jan 7, 2025 | Publications

Front Immunol. 2024 Dec 23;15:1466443. doi: 10.3389/fimmu.2024.1466443. eCollection 2024. ABSTRACT BACKGROUND: Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G...
« Older Entries
Next Entries »

Recent Content

  • Utilizing AI in Prostate Cancer Care and Management
  • KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
  • Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
  • Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
  • Op-Ed: Expand Patient Choice to Lower Medication Costs
  • Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
  • Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
  • Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
  • SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
  • GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT